Chimeric Antigen Receptors in Cancer Immuno-Gene Therapy: Current Status and Future Directions

REFERENCES

• Dudley ME, Yang JC, Sherry R, Adoptive cell therapy for patients with metastatic melanoma: evaluation of intensive myeloablative chemoradiation preparative regimens. J Clin Oncol. 2008;26(32):5233–5239.
   PubMed Web of Science ®Google Scholar
• Gross G, Gorochov G, Waks T, Eshhar Z. Generation of effector T cells expressing chimeric T cell receptor with antibody type-specificity. Transplant Proc. 1989;21(1 Pt 1):127–130.
   PubMed Web of Science ®Google Scholar
• Eshhar Z, Waks T, Gross G, Schindler DG. Specific activation and targeting of cytotoxic lymphocytes through chimeric single chains consisting of antibody-binding domains and the gamma or zeta subunits of the immunoglobulin and T-cell receptors. Proc Natl Acad Sci U S A. 1993;90(2):720–724.
   PubMed Web of Science ®Google Scholar
• Kessler JH, Melief CJ. Identification of T-cell epitopes for cancer immunotherapy. Leukemia. 2007;21(9):1859–1874.
   Google Scholar
• Finney HM, Akbar AN, Lawson AD. Activation of resting human primary T cells with chimeric receptors: costimulation from CD28, inducible costimulator, CD134, and CD137 in series with signals from the TCR zeta chain. J Immunol. 2004;172(1):104–113.
   PubMed Web of Science ®Google Scholar
• Giordano Attianese GM, Marin V, Hoyos V, In vitro and in vivo model of a novel immunotherapy approach for chronic lymphocytic leukemia by anti-CD23 chimeric antigen receptor. Blood. 2011;117(18):4736–4745.
   PubMed Web of Science ®Google Scholar
• Lamers CH, Sleijfer S, Vulto AG, Treatment of metastatic renal cell carcinoma with autologous T-lymphocytes genetically retargeted against carbonic anhydrase IX: first clinical experience. J Clin Oncol. 2006;24(13):e20–e22.
   PubMedGoogle Scholar
• Till BG, Jensen MC, Wang J, Adoptive immunotherapy for indolent non-Hodgkin lymphoma and mantle cell lymphoma using genetically modified autologous CD20-specific T cells. Blood. 2008;112(6):2261–2271.
   PubMed Web of Science ®Google Scholar
• Pule MA, Savoldo B, Myers GD, Virus-specific T cells engineered to coexpress tumor-specific receptors: persistence and antitumor activity in individuals with neuroblastoma. Nat Med. 2008;14(11):1264–1270.
   PubMed Web of Science ®Google Scholar
• Kochenderfer JN, Wilson WH, Janik JE, Eradication of B-lineage cells and regression of lymphoma in a patient treated with autologous T cells genetically engineered to recognize CD19. Blood. 2010;116(20):4099–4102.
   PubMed Web of Science ®Google Scholar
• Brentjens R, Yeh R, Bernal Y, Riviere I, Sadelain M. Treatment of chronic lymphocytic leukemia with genetically targeted autologous T cells: case report of an unforeseen adverse event in a phase I clinical trial. Mol Ther. 2010;18(4):666–668.
   PubMed Web of Science ®Google Scholar
• Morgan RA, Yang JC, Kitano M, Dudley ME, Laurencot CM, Rosenberg SA. Case report of a serious adverse event following the administration of T cells transduced with a chimeric antigen receptor recognizing ERBB2. Mol Ther. 2010;18(4):843–851.
   PubMed Web of Science ®Google Scholar
• Willemsen RA, Debets R, Hart E, Hoogenboom HR, Bolhuis RL, Chames P. A phage display selected fab fragment with MHC class I-restricted specificity for MAGE-A1 allows for retargeting of primary human T lymphocytes. Gene Ther. 2001;8(21):1601–1608.
   Google Scholar
• Willemsen RA, Ronteltap C, Chames P, Debets R, Bolhuis RL. T cell retargeting with MHC class I-restricted antibodies: the CD28 costimulatory domain enhances antigen-specific cytotoxicity and cytokine production. J Immunol. 2005;174(12):7853–7858.
   Google Scholar
• Stewart-Jones G, Wadle A, Hombach A, Rational development of high-affinity T-cell receptor-like antibodies. Proc Natl Acad Sci U S A. 2009;106(14):5784–5788.
   Google Scholar
• Li Y, Depontieu FR, Sidney J et al. Structural basis for the presentation of tumor-associated MHC class II-restricted phosphopeptides to CD4+ T cells. J Mol Biol. 2010;399(4):596–603.
   Google Scholar
• Petersen J, Wurzbacher SJ, Williamson NA, Phosphorylated self-peptides alter human leukocyte antigen class I-restricted antigen presentation and generate tumor-specific epitopes. Proc Natl Acad Sci U S A. 2009;106(8):2776–2781.
   PubMed Web of Science ®Google Scholar
• Depontieu FR, Qian J, Zarling AL, Identification of tumor-associated, MHC class II-restricted phosphopeptides as targets for immunotherapy. Proc Natl Acad Sci U S A. 2009;106(29):12073–12078.
   PubMed Web of Science ®Google Scholar
• Altenschmidt U, Kahl R, Moritz D, Cytolysis of tumor cells expressing the Neu/erbB-2, erbB-3, and erbB-4 receptors by genetically targeted naive T lymphocytes. Clin Cancer Res. 1996;2(6):1001–1008.
   PubMed Web of Science ®Google Scholar
• Kahlon KS, Brown C, Cooper LJ, Raubitschek A, Forman SJ, Jensen MC. Specific recognition and killing of glioblastoma multiforme by interleukin 13-zetakine redirected cytolytic T cells. Cancer Res. 2004;64(24):9160–9166.
   PubMed Web of Science ®Google Scholar
• Bridgeman JS, Hawkins RE, Bagley S, Blaylock M, Holland M, Gilham DE. The optimal antigen response of chimeric antigen receptors harboring the CD3zeta transmembrane domain is dependent upon incorporation of the receptor into the endogenous TCR/CD3 complex. J Immunol. 2010;184(12):6938–6949.
   PubMed Web of Science ®Google Scholar
• Bridgeman JS, Hawkins RE, Hombach AA, Building better chimeric antigen receptors for adoptive T cell therapy. Curr Gene Ther. 2010;10(2):77–90.
   PubMed Web of Science ®Google Scholar
• Brocker T, Karjalainen K. Signals through T cell receptor-zeta chain alone are insufficient to prime resting T lymphocytes. J Exp Med. 1995;181(5):1653–1659.
   PubMed Web of Science ®Google Scholar
• Brocker T. Chimeric Fv-zeta or Fv-epsilon receptors are not sufficient to induce activation or cytokine production in peripheral T cells. Blood. 2000;96(5):1999–2001.
   PubMed Web of Science ®Google Scholar
• Roberts MR, Cooke KS, Tran AC, Antigen-specific cytolysis by neutrophils and NK cells expressing chimeric immune receptors bearing zeta or gamma signaling domains. J Immunol. 1998;161(1):375–384.
   PubMed Web of Science ®Google Scholar
• Haynes NM, Snook MB, Trapani JA, Redirecting mouse CTL against colon carcinoma: superior signaling efficacy of single-chain variable domain chimeras containing TCR-zeta vs Fc epsilon RI-gamma. J Immunol. 2001;166(1):182–187.
   PubMed Web of Science ®Google Scholar
• Heuser C, Hombach A, Losch C, Manista K, Abken H. T-cell activation by recombinant immunoreceptors: impact of the intracellular signalling domain on the stability of receptor expression and antigen-specific activation of grafted T cells. Gene Ther. 2003;10(17):1408–1419.
   Google Scholar
• Zhao Y, Wang QJ, Yang S, A herceptin-based chimeric antigen receptor with modified signaling domains leads to enhanced survival of transduced T lymphocytes and antitumor activity. J Immunol. 2009;183(9):5563–5574.
   PubMed Web of Science ®Google Scholar
• Yun CO, Nolan KF, Beecham EJ, Reisfeld RA, Junghans RP. Targeting of T lymphocytes to melanoma cells through chimeric anti-GD3 immunoglobulin T-cell receptors. Neoplasia. 2000;2(5):449–459.
   Google Scholar
• Stephan MT, Ponomarev V, Brentjens RJ, T cell-encoded CD80 and 4-1BBL induce auto- and transcostimulation, resulting in potent tumor rejection. Nat Med. 2007;13(12):1440–1449.
   PubMed Web of Science ®Google Scholar
• Gade TP, Hassen W, Santos E, Targeted elimination of prostate cancer by genetically directed human T lymphocytes. Cancer Res. 2005;65(19):9080–9088.
   PubMed Web of Science ®Google Scholar
• Brentjens RJ, Santos E, Nikhamin Y, Genetically targeted T cells eradicate systemic acute lymphoblastic leukemia xenografts. Clin Cancer Res. 2007;13(18 Pt 1):5426–5435.
   PubMed Web of Science ®Google Scholar
• Mueller DL. Mechanisms maintaining peripheral tolerance. Nat Immunol. 2010;11(1):21–27.
   PubMed Web of Science ®Google Scholar
• Cooper LJ, Al-Kadhimi Z, Serrano LM, Enhanced antilymphoma efficacy of CD19-redirected influenza MP1-specific CTLs by cotransfer of T cells modified to present influenza MP1. Blood. 2005;105(4):1622–1631.
   PubMed Web of Science ®Google Scholar
• Savoldo B, Rooney CM, Di Stasi A, Epstein Barr virus specific cytotoxic T lymphocytes expressing the anti-CD30zeta artificial chimeric T-cell receptor for immunotherapy of Hodgkin disease. Blood. 2007;110(7):2620–2630.
   PubMed Web of Science ®Google Scholar
• Acuto O, Michel F. CD28-mediated co-stimulation: a quantitative support for TCR signalling. Nat Rev Immunol. 2003;3(12):939–951.
   PubMed Web of Science ®Google Scholar
• Croft M. The role of TNF superfamily members in T-cell function and diseases. Nat Rev Immunol. 2009;9(4):271–285.
   PubMed Web of Science ®Google Scholar
• Brentjens RJ, Latouche JB, Santos E, Eradication of systemic B-cell tumors by genetically targeted human T lymphocytes co-stimulated by CD80 and interleukin-15. Nat Med. 2003;9(3): 279–286.
   PubMed Web of Science ®Google Scholar
• Kowolik CM, Topp MS, Gonzalez S, CD28 costimulation provided through a CD19-specific chimeric antigen receptor enhances in vivo persistence and antitumor efficacy of adoptively transferred T cells. Cancer Res. 2006;66(22):10995–11004.
   PubMed Web of Science ®Google Scholar
• Carpenito C, Milone MC, Hassan R, Control of large, established tumor xenografts with genetically retargeted human T cells containing CD28 and CD137 domains. Proc Natl Acad Sci U S A. 2009;106(9):3360–3365.
   PubMed Web of Science ®Google Scholar
• Milone MC, Fish JD, Carpenito C, Chimeric receptors containing CD137 signal transduction domains mediate enhanced survival of T cells and increased antileukemic efficacy in vivo. Mol Ther. 2009;17(8):1453–1464.
   PubMed Web of Science ®Google Scholar
• Zhong XS, Matsushita M, Plotkin J, Chimeric antigen receptors combining 4-1BB and CD28 signaling domains augment PI3kinase/AKT/Bcl-XL activation and CD8+ T cell-mediated tumor eradication. Mol Ther. 2010;18(2):413–420.
   PubMed Web of Science ®Google Scholar
• Yvon E, Del Vecchio M, Savoldo B, Immunotherapy of metastatic melanoma using genetically engineered GD2-specific T cells. Clin Cancer Res. 2009;15(18):5852–5860.
   PubMed Web of Science ®Google Scholar
• Savoldo B, Ramos CA, Liu E, CD28 costimulation improves expansion and persistence of chimeric antigen receptor-modified T cells in lymphoma patients. J Clin Invest. 2011;121(5): 1822–1826.
   PubMed Web of Science ®Google Scholar
• Hoyos V, Savoldo B, Quintarelli C, Engineering CD19-specific T lymphocytes with interleukin-15 and a suicide gene to enhance their anti-lymphoma/leukemia effects and safety. Leukemia. 2010;24(6):1160–1170.
   PubMed Web of Science ®Google Scholar
• Di Stasi A, De Angelis B, Rooney CM, T lymphocytes coexpressing CCR4 and a chimeric antigen receptor targeting CD30 have improved homing and antitumor activity in a Hodgkin tumor model. Blood. 2009;113(25):6392-6402.
   Google Scholar
• Craddock JA, Lu A, Bear A, Enhanced tumor trafficking of GD2 chimeric antigen receptor T cells by expression of the chemokine receptor CCR2b. J Immunother. 2010;33(8):780–788.
   PubMed Web of Science ®Google Scholar
• Moon EK, Carpenito C, Sun J, Expression of a functional CCR2 receptor enhances tumor localization and eradication by human T cells expressing a mesothelin-specific chimeric antibody receptor. Clin Cancer Res. Published online May 24, 2011, doi: 10.1158/1078-0432.CCR-11-0351.
   Google Scholar
• Berger C, Jensen MC, Lansdorp PM, Gough M, Elliott C, Riddell SR. Adoptive transfer of effector CD8+ T cells derived from central memory cells establishes persistent T cell memory in primates. J Clin Invest. 2008;118(1):294–305.
   PubMed Web of Science ®Google Scholar
• Klebanoff CA, Gattinoni L, Torabi-Parizi P, Central memory self/tumor-reactive CD8+ T cells confer superior antitumor immunity compared with effector memory T cells. Proc Natl Acad Sci U S A. 2005;102(27):9571–9576.
   PubMed Web of Science ®Google Scholar
• Singh H, Manuri PR, Olivares S, Redirecting specificity of T-cell populations for CD19 using the Sleeping Beauty system. Cancer Res. 2008;68(8):2961–2971.
   PubMed Web of Science ®Google Scholar
• Gattinoni L, Klebanoff CA, Palmer DC, Acquisition of full effector function in vitro paradoxically impairs the in vivo antitumor efficacy of adoptively transferred CD8+ T cells. J Clin Invest. 2005;115(6):1616–1626.
   PubMed Web of Science ®Google Scholar
• Yang S, Luca G, Liu F, In vitro generated anti-tumor T lymphocytes exhibit distinct subsets mimicking in vivo antigen-experienced cells. Cancer Immunol Immunother. 2011;60(5):739–749.
   PubMed Web of Science ®Google Scholar
• Neeson P, Shin A, Tainton KM, Ex vivo culture of chimeric antigen receptor T cells generates functional CD8+ T cells with effector and central memory-like phenotype. Gene Ther. 2010;17(9):1105–1116.
   PubMed Web of Science ®Google Scholar
• Popplewell L. Genetically engineered lymphocyte therapy after peripheral blood stem cell transplant in treating patients with high-risk, intermediate-grade, B-cell non-Hodgkin lymphoma. National Clinical Trials [Internet]. 2011 Mar 16; NCT01318317. Available from: clinicaltrials.gov/ct2/show/ record/NCT01318317
   Google Scholar
• Hinrichs CS, Borman ZA, Cassard L, Adoptively transferred effector cells derived from naive rather than central memory CD8+ T cells mediate superior antitumor immunity. Proc Natl Acad Sci U S A. 2009;106(41):17469–17474.
   PubMed Web of Science ®Google Scholar
• Imai C, Iwamoto S, Campana D. Genetic modification of primary natural killer cells overcomes inhibitory signals and induces specific killing of leukemic cells. Blood. 2005;106(1):376–383.
   PubMed Web of Science ®Google Scholar
• Muller T, Uherek C, Maki G, Expression of a CD20-specific chimeric antigen receptor enhances cytotoxic activity of NK cells and overcomes NK-resistance of lymphoma and leukemia cells. Cancer Immunol Immunother. 2008;57(3):411–423.
   PubMed Web of Science ®Google Scholar
• Marin V, Dander E, Biagi E, Characterization of in vitro migratory properties of anti-CD19 chimeric receptor-redirected CIK cells for their potential use in B-ALL immunotherapy. Exp Hematol. 2006;34(9):1219–1229.
   PubMed Web of Science ®Google Scholar
• Gong Q, Ou Q, Ye S, Importance of cellular microenvironment and circulatory dynamics in B cell immunotherapy. J Immunol. 2005;174(2):817–826.
   PubMed Web of Science ®Google Scholar
• Chan CH, Stanners CP. Novel mouse model for carcinoembryonic antigen-based therapy. Mol Ther. 2004;9(6):775–785.
   PubMed Web of Science ®Google Scholar
• Kochenderfer JN, Yu Z, Frasheri D, Restifo NP, Rosenberg SA. Adoptive transfer of syngeneic T cells transduced with a chimeric antigen receptor that recognizes murine CD19 can eradicate lymphoma and normal B cells. Blood. 2010;116(19):3875–3886.
   PubMed Web of Science ®Google Scholar
• Cheadle EJ, Hawkins RE, Batha H, O'Neill AL, Dovedi SJ, Gilham DE. Natural expression of the CD19 antigen impacts the long-term engraftment but not antitumor activity of CD19-specific engineered T cells. J Immunol. 2010;184(4):1885–1896.
   PubMed Web of Science ®Google Scholar
• Shultz LD, Ishikawa F, Greiner DL. Humanized mice in translational biomedical research. Nat Rev Immunol. 2007;7(2):118–130.
   PubMed Web of Science ®Google Scholar
• Lee JC, Hayman E, Pegram HJ, In vivo inhibition of human CD19-targeted effector T cells by natural T regulatory cells in a xenotransplant murine model of B cell malignancy. Cancer Res. 2011;71(8):2871–2881.
   Google Scholar
• Pike-Overzet K, van der Burg M, Wagemaker G, van Dongen JJ, Staal FJ. New insights and unresolved issues regarding insertional mutagenesis in X-linked SCID gene therapy. Mol Ther. 2007;15(11):1910–1916.
   PubMed Web of Science ®Google Scholar
• Huang X, Guo H, Kang J, Sleeping Beauty transposon-mediated engineering of human primary T cells for therapy of CD19+ lymphoid malignancies. Mol Ther. 2008;16(3):580–589.
   PubMed Web of Science ®Google Scholar
• Manuri PV, Wilson MH, Maiti SN, piggyBac transposon/transposase system to generate CD19-specific T cells for the treatment of B-lineage malignancies. Hum Gene Ther. 2010;21(4):427–437.
   Google Scholar
• Jin Z, Maiti S, Huls H, The hyperactive Sleeping Beauty transposase SB100X improves the genetic modification of T cells to express a chimeric antigen receptor. Gene Ther. 2011.
   Web of Science ®Google Scholar
• Bonini C, Grez M, Traversari C, Safety of retroviral gene marking with a truncated NGF receptor. Nat Med. 2003;9(4):367–369.
   PubMed Web of Science ®Google Scholar
• Newrzela S, Cornils K, Li Z, Resistance of mature T cells to oncogene transformation. Blood. 2008;112(6):2278–2286.
   Google Scholar
• DeKelver RC, Choi VM, Moehle EA, Functional genomics, proteomics, and regulatory DNA analysis in isogenic settings using zinc finger nuclease-driven transgenesis into a safe harbor locus in the human genome. Genome Res. 2010;20(8):1133–1142.
   PubMed Web of Science ®Google Scholar
• Zou J, Sweeney CL, Chou BK, Oxidase deficient neutrophils from X-linked chronic granulomatous disease iPS cells: functional correction by zinc finger nuclease mediated safe harbor targeting. Blood. 2011.
   Google Scholar
• Zhao Y, Moon E, Carpenito C, Multiple injections of electroporated autologous T cells expressing a chimeric antigen receptor mediate regression of human disseminated tumor. Cancer Res. 2010;70(22):9053–9061.
   PubMed Web of Science ®Google Scholar
• Mitsuyasu RT, Anton PA, Deeks SG, Prolonged survival and tissue trafficking following adoptive transfer of CD4zeta gene-modified autologous CD4(+) and CD8(+) T cells in human immunodeficiency virus-infected subjects. Blood. 2000;96(3):785–793.
   PubMed Web of Science ®Google Scholar
• Wang J, Press OW, Lindgren CG, Cellular immunotherapy for follicular lymphoma using genetically modified CD20-specific CD8+ cytotoxic T lymphocytes. Mol Ther. 2004;9(4):577–586.
   PubMed Web of Science ®Google Scholar
• Park JR, Digiusto DL, Slovak M, Adoptive transfer of chimeric antigen receptor re-directed cytolytic T lymphocyte clones in patients with neuroblastoma. Mol Ther. 2007;15(4):825–833.
   PubMed Web of Science ®Google Scholar
• Kershaw MH, Westwood JA, Parker LL, A phase I study on adoptive immunotherapy using gene-modified T cells for ovarian cancer. Clin Cancer Res. 2006;12(20 Pt 1):6106–6115.
   PubMed Web of Science ®Google Scholar
• Brentjens R, Riviere I. Laboratory-treated T cells with or without cyclophosphamide in treating patients with refractory chronic lymphocytic leukemia. National Clinical Trials [Internet]. 2007 Apr 25; NCT00466531. Available from: clinicaltrials.gov/ct2/show/NCT00466531
   Google Scholar
• Brentjens R. Precursor B cell acute lymphoblastic leukemia (B-ALL) treated with autologous T cells genetically targeted to the B cell specific antigen CD19. National Clinical Trials [Internet]. 2010 Jan 6; NCT01044069. Available from: clinicaltrials.gov/ct2/show/NCT01044069
   Google Scholar
• Ertl HC, Zaia J, Rosenberg SA, Considerations for the clinical application of chimeric antigen receptor T cells: observations from a Recombinant DNA Advisory Committee symposium held June 15, 2010. Cancer Res. 2011;71(9):3175–3181.
   Google Scholar
• Bonini C, Ferrari G, Verzeletti S, HSV-TK gene transfer into donor lymphocytes for control of allogeneic graft-versus-leukemia. Science. 1997;276(5319):1719–1724.
   PubMed Web of Science ®Google Scholar
• Di Stasi A, Tey SK, Fujita Y, CASPALLO: Phase I clinical trial of allodepleted T cells transduced with inducible caspase 9 suicide gene after haploidentical stem cell transplantation. ASH Annual Meeting Abstracts 2010;116(21):559–.
   Google Scholar
• Serafini M, Bonamino M, Golay J, Introna M. Elongation factor 1 (EF1alpha) promoter in a lentiviral backbone improves expression of the CD20 suicide gene in primary T lymphocytes allowing efficient rituximab-mediated lysis. Haematologica. 2004;89(1):86–95.
   Google Scholar
• Serafini M, Manganini M, Borleri G, Characterization of CD20-transduced T lymphocytes as an alternative suicide gene therapy approach for the treatment of graft-versus-host disease. Hum Gene Ther. 2004;15(1):63–76.
   Google Scholar
• Vogler I, Newrzela S, Hartmann S, An improved bicistronic CD20/tCD34 vector for efficient purification and in vivo depletion of gene-modified T cells for adoptive immunotherapy. Mol Ther. 2010;18(7):1330–1338.
   PubMed Web of Science ®Google Scholar
• Kershaw MH, Teng MW, Smyth MJ, Darcy PK. Supernatural T cells: genetic modification of T cells for cancer therapy. Nat Rev Immunol. 2005;5(12):928–940.
   PubMed Web of Science ®Google Scholar
• Varela-Rohena A, Carpenito C, Perez EE, Genetic engineering of T cells for adoptive immunotherapy. Immunol Res. 2008;42(1-3):166–181.
   Google Scholar
• Duong CP, Westwood JA, Berry LJ, Darcy PK, Kershaw MH. Enhancing the specificity of T-cell cultures for adoptive immunotherapy of cancer. Immunotherapy. 2011;3(1):33–48.
   Google Scholar
• ESGCT Poster presentations. XVIII Annual Congress of the European Society of Gene and Cell Therapy. Hum Gene Ther. 2010; 21:1397–1488.
   Google Scholar
• Turatti F, Figini M, Balladore E, Redirected activity of human antitumor chimeric immune receptors is governed by antigen and receptor expression levels and affinity of interaction. J Immunother. 2007;30(7):684–693.
   PubMed Web of Science ®Google Scholar
• Chmielewski M, Hombach A, Heuser C, T cell activation by antibody-like immunoreceptors: increase in affinity of the single-chain fragment domain above threshold does not increase T cell activation against antigen-positive target cells but decreases selectivity. J Immunol. 2004;173(12):7647–7653.
   PubMed Web of Science ®Google Scholar
• Morgan RA, Dudley ME, Wunderlich JR, Cancer regression in patients after transfer of genetically engineered lymphocytes. Science. 2006;314(5796):126–129.
   PubMed Web of Science ®Google Scholar
• Johnson LA, Morgan RA, Dudley ME, Gene therapy with human and mouse T-cell receptors mediates cancer regression and targets normal tissues expressing cognate antigen. Blood. 2009;114(3):535–546.
   PubMed Web of Science ®Google Scholar
• Bendle GM, Linnemann C, Hooijkaas AI, Lethal graft-versus-host disease in mouse models of T cell receptor gene therapy. Nat Med. 2010;16(5):565–570, 1p following 70.
   PubMed Web of Science ®Google Scholar
• Rosenberg SA. Of mice, not men: no evidence for graft-versus-host disease in humans receiving T-cell receptor-transduced autologous T cells. Mol Ther. 2010;18(10):1744–1745.
   Google Scholar
• Robbins PF, Morgan RA, Feldman SA, Tumor regression in patients with metastatic synovial cell sarcoma and melanoma using genetically engineered lymphocytes reactive with NY-ESO-1. J Clin Oncol. 2011;29(7):917–924..
   PubMed Web of Science ®Google Scholar
• Guest RD, Hawkins RE, Kirillova N, The role of extracellular spacer regions in the optimal design of chimeric immune receptors: evaluation of four different scFvs and antigens. J Immunother. 2005;28(3):203–211.
   PubMed Web of Science ®Google Scholar